LongeVC partners Sergey Jakimov and Artem Trotsyuk co-authored an article on how artificial intelligence, when paired with the scientific method, could reshape drug discovery. They describe the limits of AI on its own and the potential of embedding it into structured, iterative experimentation to improve reliability, speed, and transparency in the discovery process.
Examples include Insilico Medicine’s rapid design of a novel drug candidate, Deep Longevity’s use of predictive biomarkers, and the emergence of automated cloud labs that support continuous learning. The piece highlights that the true breakthrough will come when algorithms and experiments operate together in closed-loop systems that generate and test hypotheses in real time.
Read the full article here.
Examples include Insilico Medicine’s rapid design of a novel drug candidate, Deep Longevity’s use of predictive biomarkers, and the emergence of automated cloud labs that support continuous learning. The piece highlights that the true breakthrough will come when algorithms and experiments operate together in closed-loop systems that generate and test hypotheses in real time.
Read the full article here.